What is the appropriate management for a patient on prednisone 15 mg daily with a urine protein‑to‑creatinine ratio that rose from 138 mg/g to 3711 mg/g?

Escalate Immunosuppression Immediately

This patient requires urgent intensification of therapy with addition of a calcineurin inhibitor (CNI) or mycophenolate mofetil (MMF) to the current prednisone regimen, as the dramatic rise in proteinuria from 138 to 3711 mg/g indicates treatment failure on low-dose corticosteroids alone.

Clinical Context

The urine protein-to-creatinine ratio (UPCR) has increased 27-fold, from 138 mg/g (essentially normal) to 3711 mg/g (nephrotic-range proteinuria, defined as >3500 mg/g). This represents either:

• A relapse of previously controlled nephrotic syndrome
• Progression of underlying glomerular disease
• Steroid-resistant disease becoming apparent

The current prednisone dose of 15 mg daily is insufficient for active nephrotic syndrome and represents a maintenance or tapering dose rather than therapeutic immunosuppression.

Immediate Management Algorithm

Step 1: Add Second-Line Immunosuppression

Based on the most likely diagnosis of focal segmental glomerulosclerosis (FSGS) or membranous nephropathy given nephrotic-range proteinuria:

First choice: Calcineurin Inhibitor 1

• Cyclosporine: Start at 3-5 mg/kg/day in 2 divided doses
  • Target trough level: 100-175 ng/mL
• OR Tacrolimus: Start at 0.05-0.1 mg/kg/day in 2 divided doses
  • Target trough level: 5-10 ng/mL
• Continue for minimum 4-6 months before declaring treatment failure 1
• If partial or complete remission achieved by 6 months, continue for at least 12 months total 1

Alternative: Mycophenolate Mofetil 1

• Target dose: 2-3 g/day (or mycophenolic acid at equivalent dose)
• Particularly appropriate if CNI contraindicated or concerns about nephrotoxicity

Step 2: Optimize Corticosteroid Dosing

The current 15 mg daily dose is inadequate for active disease. Two options:

Option A: If adding CNI 1

• Combine with low-dose corticosteroids
• Continue prednisone 0.3-0.5 mg/kg/day (approximately 20-35 mg for average adult)
• Taper to ≤7.5 mg/day over 3-6 months as proteinuria improves

Option B: If CNI not immediately available 1

• Consider pulse IV methylprednisolone 500-2500 mg total dose
• Followed by oral prednisone 0.3-0.5 mg/kg/day
• This is a temporizing measure while arranging CNI therapy

Step 3: Supportive Care

• ACE inhibitor or ARB: Mandatory for antiproteinuric effect 1
• Hydroxychloroquine: If lupus nephritis suspected 2, 3
• Monitor for complications of nephrotic syndrome:
  • Thromboembolism risk (consider prophylactic anticoagulation if albumin <2.5 g/dL)
  • Infection risk
  • Hyperlipidemia

Treatment Duration and Monitoring

Assess response at defined intervals 1:

• 3 months: Expect ≥25% reduction in proteinuria
• 6 months: Expect ≥50% reduction in proteinuria
• 12 months: Target UPCR <500-700 mg/g (complete clinical response)

If no response after 6 months of CNI therapy (defined as <50% reduction in proteinuria):

• Consider alternative immunosuppression
• Reassess diagnosis with repeat kidney biopsy if not previously performed
• Consider genetic testing if FSGS suspected 1

Critical Pitfalls to Avoid

1. Do not continue current regimen: 15 mg prednisone alone is insufficient for nephrotic-range proteinuria and will lead to progressive kidney damage 1

2. Do not use cyclophosphamide as first-line: While effective in some contexts, CNIs and MMF have superior efficacy/toxicity ratios for most nephrotic syndromes 1

3. Do not delay kidney biopsy if not yet performed: Histologic diagnosis is essential for optimal management, especially with UPCR >500 mg/g 1

4. Monitor CNI nephrotoxicity: If serum creatinine increases >30% from baseline and doesn't plateau, reduce CNI dose or discontinue 1

5. Avoid abrupt steroid withdrawal: Even at 15 mg daily, taper gradually to prevent adrenal insufficiency 4

Special Considerations

If this represents lupus nephritis (Class V with nephrotic-range proteinuria):

• MMF 2-3 g/day is preferred first-line agent 2, 3
• Combine with pulse IV methylprednisolone followed by oral prednisone 20 mg/day, tapered to ≤5 mg/day by 3 months 2
• Add hydroxychloroquine (dose not exceeding 5 mg/kg/day) 2

If patient has contraindications to both CNI and MMF:

• Consider rituximab (off-label but increasingly used)
• High-dose corticosteroids alone (less preferred due to toxicity)
• Combination therapy with azathioprine 1

The dramatic rise in proteinuria demands urgent action—continuing the current low-dose prednisone monotherapy will result in progressive glomerular damage and potential kidney failure.